Hereditary angioedemaNews & Research
18 curated articles for Hereditary angioedema — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.
- The World Allergy Organization journal May 21, 2026
Toward equitable and evidence-based care in Hereditary Angioedema: Time for inclusive global guidelines.
Toward equitable and evidence-based care in Hereditary Angioedema: Time for inclusive global guidelines.
Why it matters: Recent peer-reviewed research on Hereditary angioedema that may be relevant for patients and caregivers.
- Journal of clinical medicine May 13, 2026
The Hereditary Angioedema Frailty and Inflammation Score (HAE-FIS): A Preliminary Study on the Inter-Attack Chronic Burden.
Background/Objectives: Current management of Hereditary Angioedema (HAE) predominantly focuses on acute attack control and prophylaxis. However, the cumulative "inter-attack" burden driven by chronic low-grade inflammation and its impact on physical frailty remain under-investigated. This preliminar...
Why it matters: Recent peer-reviewed research on Hereditary angioedema that may be relevant for patients and caregivers.
- Journal of asthma and allergy May 11, 2026
Drug Patterns and Economic Costs Among Patients with Hereditary Angioedema.
This study explored real-world patterns of subcutaneous (SC) long-term prophylaxis (LTP), prescriptions for on-demand treatment (ODT), and treatment-related expenditures among patients with hereditary angioedema (HAE). This study was conducted using a retrospective cohort design and US healthcare cl...
Why it matters: Recent peer-reviewed research on Hereditary angioedema that may be relevant for patients and caregivers.
- Medicina (Kaunas, Lithuania) May 4, 2026
Quality of Life and Socioeconomic Situation of Patients with Hereditary Angioedema in Slovakia.
Background and Objectives : Hereditary angioedema (HAE) represents a specific form of life-threatening inborn errors of immunity. Current guidelines recommend regular assessment of the disease burden, disease control and quality of life. This study describes the profile of HAE patients in Slovakia, ...
Why it matters: Recent peer-reviewed research on Hereditary angioedema that may be relevant for patients and caregivers.
- Frontiers in immunology Apr 22, 2026
Eosinophilic inflammation in hereditary angioedema: a single-center real-world retrospective chart review study.
Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent, unpredictable swelling attacks primarily driven by bradykinin-mediated vascular permeability. However, additional inflammatory mechanisms may contribute to disease heterogeneity. During routine diagnostics, we observe...
Why it matters: Recent peer-reviewed research on Hereditary angioedema that may be relevant for patients and caregivers.
- Orphanet journal of rare diseases Apr 22, 2026
Mast cell mediators in hereditary angioedema.
Mast cell mediators in hereditary angioedema.
Why it matters: Recent peer-reviewed research on Hereditary angioedema that may be relevant for patients and caregivers.
- The Journal of allergy and clinical immunology Apr 5, 2026
Updates in hereditary angioedema and chronic spontaneous urticaria.
Hereditary angioedema (HAE) is a genetic disorder caused by either deficiency of C1 esterase inhibitor (85% of cases) or normal to high levels of nonfunctional C1 esterase inhibitor. Both defects lead to dysregulation of the kallikrein pathway, unregulated bradykinin production, and episodic swellin...
Why it matters: Recent peer-reviewed research on Hereditary angioedema that may be relevant for patients and caregivers.
- Cardiology in review Mar 20, 2026
Hereditary Angioedema.
Hereditary angioedema is a rare and disabling disorder caused by mutations in the SERPING1 gene. These mutations ultimately lead to deficient or dysfunctional C1 esterase inhibitor and unregulated activation of the kallikrein-kinin system. This review discusses the current epidemiology, etiology, an...
Why it matters: Recent peer-reviewed research on Hereditary angioedema that may be relevant for patients and caregivers.
- Allergy and asthma proceedings Mar 17, 2026
Rethinking the management of hereditary angioedema.
Background: Hereditary angioedema with C1INH deficiency (HAE-C1INH) is a rare, debilitating genetic disorder characterized by recurrent, unpredictable attacks. Although treatments exist, patients with HAE still alter their lives to avoid triggers and experience substantial physical, psychosocial, an...
Why it matters: Recent peer-reviewed research on Hereditary angioedema that may be relevant for patients and caregivers.
- Frontiers in immunology Mar 13, 2026
Epidemiological and clinical characteristics of hereditary angioedema in the Baltic states.
Hereditary angioedema (HAE) is a rare, potentially life-threatening disorder characterised by recurrent episodes of localised oedema caused by bradykinin overproduction. Accurate epidemiological data are essential for optimising diagnosis and treatment, particularly in underrepresented regions such ...
Why it matters: Recent peer-reviewed research on Hereditary angioedema that may be relevant for patients and caregivers.
- Allergy Feb 17, 2026
International Guideline on the Diagnosis and Management of Pediatric Patients With Hereditary Angioedema.
Hereditary angioedema (HAE) with C1 inhibitor deficiency is a rare disease characterized by unpredictable episodes of tissue swelling (angioedema), which, in most cases, occur first under the age of 18 years, and entail a significant burden of disease not only for the patients but also for th...
Why it matters: Recent peer-reviewed research on Hereditary angioedema that may be relevant for patients and caregivers.
- The World Allergy Organization journal Feb 12, 2026
Clinical features of hereditary angioedema involving the gastrointestinal tract: A retrospective analysis.
Hereditary angioedema (HAE) is a rare, severe, disabling, and life-threatening disorder characterized by recurrent and unpredictable edema of skin and mucous membranes. Gastrointestinal edema, often presenting as abdominal pain, is common but frequently misdiagnosed, leading to unnecessary surgeries...
Why it matters: Recent peer-reviewed research on Hereditary angioedema that may be relevant for patients and caregivers.
- Annals of medicine and surgery (2012) Feb 12, 2026
"Emerging role of plasma kallikrein inhibitors in preventing hereditary angioedema flares in pregnancy".
Hereditary angioedema (HAE) presents a significant therapeutic challenge during pregnancy, a period often associated with increased attack frequency and severity. The management of HAE in pregnancy is complicated by physiological changes and limited fetal safety data for many prophylactic agents. Re...
Why it matters: Recent peer-reviewed research on Hereditary angioedema that may be relevant for patients and caregivers.
- The World Allergy Organization journal Feb 9, 2026
Developing a patient journey map to improve care and experience in Chinese patients with hereditary angioedema.
Hereditary angioedema (HAE) is a rare disorder that imposes a substantial burden on patient health and quality of life. Although international studies have highlighted specific aspects of the HAE care continuum, comprehensive evidence on patient experiences in China remains scarce. We conducted a si...
Why it matters: Recent peer-reviewed research on Hereditary angioedema that may be relevant for patients and caregivers.
- The journal of allergy and clinical immunology. In practice Feb 7, 2026
Updates on the Current and Evolving Treatment for Hereditary Angioedema.
Hereditary angioedema (HAE) with C1-inhibitor deficiency is a rare condition presenting with episodes of swelling without urticaria. Historically, acute and prophylactic HAE treatment options were limited and associated with considerable side effects, high burden of treatment, and unreliable symptom...
Why it matters: Recent peer-reviewed research on Hereditary angioedema that may be relevant for patients and caregivers.
- Allergy Feb 4, 2026
Algorithms in Allergy: Hereditary Angioedema.
Algorithms in Allergy: Hereditary Angioedema.
Why it matters: Recent peer-reviewed research on Hereditary angioedema that may be relevant for patients and caregivers.
- Drugs Jan 31, 2026
Donidalorsen: First Approval.
Donidalorsen (DAWNZERA™) is a first-in-class, RNA-targeted antisense oligonucleotide (ASO), developed by Ionis Pharmaceuticals for the prevention of hereditary angioedema (HAE) attacks. It received its first approval on 21 August 2025 in the USA for the prophylaxis of HAE attacks in adult and...
Why it matters: Recent peer-reviewed research on Hereditary angioedema that may be relevant for patients and caregivers.
- Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology Jan 29, 2026
The International/Canadian hereditary angioedema guideline.
This update to the 2019 Canadian Hereditary Angioedema (HAE) Guideline broadens its focus to include the management of patients with HAE worldwide, building on its established international framework. It has been developed through a collaboration of Canadian and international HAE experts and patient...
Why it matters: Recent peer-reviewed research on Hereditary angioedema that may be relevant for patients and caregivers.
More on Hereditary angioedema
Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.